The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Molecular Predictors of Progression-Free and Overall Survival in Patients With Newly Diagnosed Glioblastoma: A Prospective Translational Study of the German Glioma Network
Open accessAbstract
Purpose: The prognostic value of genetic alterations characteristic of glioblastoma in patients treated according to present standards of care is unclear. Patients and Methods: Three hundred one patients with glioblastoma were prospectively recruited between October 2004 and December 2006 at the clinical centers of the German Glioma Network. Two hundred fifty-eight patients had radiotherapy, 199 patients had temozolomide, 189 had both, and seven had another chemotherapy as the initial treatment. The tumors were investigated for TP53 mutation, p53 immunoreactivity, epidermal growth factor receptor, cyclin-dependent kinase CDK 4 or murine double minute 2 amplification, CDKN2A homozygous deletion, allelic losses on chromosome arms 1p, 9p, 10q, and 19q, O 6 -methylguanine methyltransferase (MGMT) promoter methylation, and isocitrate dehydrogenase 1 (IDH1) mutations. Results: Median progression-free (PFS) and overall survival (OS) were 6.8 and 12.5 months. Multivariate analysis revealed younger age, higher performance score, MGMT promoter methylation, and temozolomide radiochemotherapy as independent factors associated with longer OS. MGMT promoter methylation was associated with longer PFS (relative risk [RR], 0.5; 95% CI, 0.38 to 0.68; P < .001) and OS (RR, 0.39; 95% CI, 0.28 to 0.54; P < .001) in patients receiving temozolomide. IDH1 mutations were associated with prolonged PFS (RR, 0.42; 95% CI, 0.19 to 0.91; P = .028) and a trend for prolonged OS (RR, 0.43; 95% CI, 0.15 to 1.19; P = .10). No other molecular factor was associated with outcome. Conclusion: Molecular changes associated with gliomagenesis do not predict response to therapy in glioblastoma patients managed according to current standards of care. MGMT promoter methylation and IDH1 mutational status allow for stratification into prognostically distinct subgroups.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing
Benjamini, Y., & Hochberg, Y. (1995) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1995.tb02031.x · Cited by 109,482
Radiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma
Stupp, R., Mason, W. P., van den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J. B., Belanger, K., Brandes, A. A., Marosi, C., Bogdahn, U., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043330 · Cited by 21,807
Self-citationThe 2007 WHO Classification of Tumours of the Central Nervous System
Louis, D. N., Ohgaki, H., Wiestler, O. D., Cavenee, W. K., Burger, P. C., Jouvet, A., Scheithauer, B. W., & Kleihues, P. (2007) · Acta Neuropathologica · doi:10.1007/s00401-007-0243-4 · Cited by 15,397
Self-citationComprehensive genomic characterization defines human glioblastoma genes and core pathways
The Cancer Genome Atlas Research Network (2008) · Nature · doi:10.1038/nature07385 · Cited by 7,735
MGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma
Hegi, M. E., Diserens, A.-C., Gorlia, T., Hamou, M.-F., de Tribolet, N., Weller, M., Kros, J. M., Hainfellner, J. A., Mason, W., Mariani, L., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043331 · Cited by 7,405
Self-citationAn Integrated Genomic Analysis of Human Glioblastoma Multiforme
Parsons, D. W., Jones, S., Zhang, X., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Siu, I.-M., Gallia, G. L., et al. (2008) · Science · doi:10.1126/science.1164382 · Cited by 5,857
IDH1 and IDH2 Mutations in Gliomas
Yan, H., Parsons, D. W., Jin, G., McLendon, R., Rasheed, B. A., Yuan, W., Kos, I., Batinic-Haberle, I., Jones, S., Riggins, G. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808710 · Cited by 5,847
Inactivation of the DNA-Repair Gene MGMT and the Clinical Response of Gliomas to Alkylating Agents
Esteller, M., Garcia-Foncillas, J., Andion, E., Goodman, S. N., Hidalgo, O. F., Vanaclocha, V., Baylin, S. B., & Herman, J. G. (2000) · New England Journal of Medicine · doi:10.1056/nejm200011093431901 · Cited by 2,224
Genetic Pathways to Glioblastoma
Ohgaki, H., Dessen, P., Jourde, B., Horstmann, S., Nishikawa, T., Di Patre, P.-L., Burkhard, C., Schüler, D., Probst-Hensch, N. M., Maiorka, P. C., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1337 · Cited by 1,270
Analysis of the IDH1 codon 132 mutation in brain tumors
Balss, J., Meyer, J., Mueller, W., Korshunov, A., Hartmann, C., & von Deimling, A. (2008) · Acta Neuropathologica · doi:10.1007/s00401-008-0455-2 · Cited by 1,036
Self-citationLong-term survival with glioblastoma multiforme
Krex, D., Klink, B., Hartmann, C., von Deimling, A., Pietsch, T., Simon, M., Sabel, M., Steinbach, J. P., Heese, O., Reifenberger, G., et al. (2007) · Brain · doi:10.1093/brain/awm204 · Cited by 887
Self-citationvan den Bent, M. J., Carpentier, A. F., Brandes, A. A., Sanson, M., Taphoorn, M. J. B., Bernsen, H. J. J. A., Frenay, M., Tijssen, C. C., Grisold, W., Sipos, L., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.6078 · Cited by 748
Cairncross, G., Berkey, B., Shaw, E., Jenkins, R., Scheithauer, B., Brachman, D., Buckner, J., Fink, K., Souhami, L., Laperierre, N., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.3414 · Cited by 728
Mirimanoff, R.-O., Gorlia, T., Mason, W., Van den Bent, M. J., Kortmann, R.-D., Fisher, B., Reni, M., Brandes, A. A., Curschmann, J., Villa, S., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.5963 · Cited by 509
Liang, Y., Diehn, M., Watson, N., Bollen, A. W., Aldape, K. D., Nicholas, M. K., Lamborn, K. R., Berger, M. S., Botstein, D., Brown, P. O., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0402870102 · Cited by 503
Gene expression profiling and genetic markers in glioblastoma survival
Rich, J. N., Hans, C., Jones, B., Iversen, E. S., McLendon, R. E., Rasheed, B. K. A., Dobra, A., Dressman, H. K., Bigner, D. D., Nevins, J. R., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-3936 · Cited by 316
Hermisson, M., Klumpp, A., Wick, W., Wischhusen, J., Nagel, G., Roos, W., Kaina, B., & Weller, M. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2005.03583.x · Cited by 311
Self-citationReifenberger, G., REIFENBERGER, J., Ichimura, K., Meltzer, P. S., & Collins, V. P. (1994) · PubMed · Cited by 279
Self-citationFrequent promoter hypermethylation and low expression of the MGMT gene in oligodendroglial tumors
Möllemann, M., Wolter, M., Felsberg, J., Collins, V. P., & Reifenberger, G. (2005) · International Journal of Cancer · doi:10.1002/ijc.20575 · Cited by 278
Self-citationAge-Dependent Prognostic Effects of Genetic Alterations in Glioblastoma
Batchelor, T. T., Betensky, R. A., Esposito, J. M., Pham, L.-D. D., Dorfman, M. V., Piscatelli, N., Jhung, S., Rhee, D., & Louis, D. N. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-0841-3 · Cited by 200
Pathology and molecular genetics of astrocytic gliomas
Reifenberger, G., & Collins, V. P. (2004) · Journal of Molecular Medicine · doi:10.1007/s00109-004-0564-x · Cited by 193
Self-citationFelsberg, J., Erkwoh, A., Sabel, M. C., Kirsch, L., Fimmers, R., Blaschke, B., Schlegel, U., Schramm, J., Wiestler, O. D., & Reifenberger, G. (2004) · Brain Pathology · doi:10.1111/j.1750-3639.2004.tb00044.x · Cited by 173
Self-citationKim, T.-Y., Zhong, S., Fields, C. R., Kim, J. H., & Robertson, K. D. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4552 · Cited by 171
Herrlinger, U., Rieger, J., Koch, D., Loeser, S., Blaschke, B., Kortmann, R.-D., Steinbach, J. P., Hundsberger, T., Wick, W., Meyermann, R., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.9104 · Cited by 166
Self-citationKrishnan, A. Y., Nademanee, A. P., Fung, H. C. H., Raubitschek, A. A., Molina, A., Yamauchi, D. M., Rodríguez, R., Spielberger, R. T., Falk, P., Palmer, J. M., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.9248 · Cited by 161
Prognostic impact of molecular markers in a series of 220 primary glioblastomas
Houillier, C., Lejeune, J., Benouaich‐Amiel, A., Laigle–Donadey, F., Crinière, E., Mokhtari, K., Thillet, J., Delattre, J., Hoang‐Xuan, K., & Sanson, M. (2006) · Cancer · doi:10.1002/cncr.21819 · Cited by 159
Glas, M., Hertler, C., Rieger, J., Wiewrodt, D., Bähr, O., Steinbach, J. P., Wick, W., Kortmann, R., Reifenberger, G., Weller, M., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.2195 · Cited by 134
Self-citationMGMT prognostic impact on glioblastoma is dependent on therapeutic modalities
Crinière, E., Kaloshi, G., Laigle–Donadey, F., Lejeune, J., Auger, N., Benouaich‐Amiel, A., Everhard, S., Mokhtari, K., Polivka, M., Delattre, J., et al. (2007) · Journal of Neuro-Oncology · doi:10.1007/s11060-006-9320-0 · Cited by 93
Rolhion, C., Penault-Llorca, F., Kémény, J., Kwiatkowski, F., Lemaire, J., Chollet, P. J. M., Finat-Duclos, F., & Verrelle, P. (1999) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19990820)84:4<416::aid-ijc15>3.0.co;2-a · Cited by 63
Kaulich, K., Blaschke, B., Nümann, A., von Deimling, A., Wiestler, O. D., Weber, R. G., & Reifenberger, G. (2002) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/61.12.1092 · Cited by 63
Self-citationMolecular Genetic Analysis of Oligodendroglial Tumors
Hartmann, C. J., Mueller, W. C., Laß, U., Kamel‐Reid, S., & von Deimling, A. (2005) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/64.1.10 · Cited by 57
Self-citation
Research works printed but not linked: 2
- P Kleihues, PC Burger, VP Collins , etal: WHO classification of tumours of the nervous system 29– 39,2000 Lyon, France IARC Press
- Reifenberger G, 1994, Cancer Res, 54, 4299
Cited by
Hartmann, C., Hentschel, B., Wick, W., Capper, D., Felsberg, J., Simon, M., Westphal, M., Schackert, G., Meyermann, R., Pietsch, T., et al. (2010) · Acta Neuropathologica · doi:10.1007/s00401-010-0781-z · Cited by 829
Self-citationMGMT promoter methylation in malignant gliomas: ready for personalized medicine?
Weller, M., Stupp, R., Reifenberger, G., Brandes, A. A., van den Bent, M. J., Wick, W., & Hegi, M. E. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2009.197 · Cited by 778
Self-citationGlioblastoma: pathology, molecular mechanisms and markers
Aldape, K., Zadeh, G., Mansouri, S., Reifenberger, G., & von Deimling, A. (2015) · Acta Neuropathologica · doi:10.1007/s00401-015-1432-1 · Cited by 735
Self-citationGenetic and molecular epidemiology of adult diffuse glioma
Molinaro, A. M., Taylor, J. W., Wiencke, J. K., & Wrensch, M. R. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-019-0220-2 · Cited by 709
Molinaro, A. M., Hervey-Jumper, S., Morshed, R. A., Young, J., Han, S. J., Chunduru, P., Zhang, Y., Phillips, J. J., Shai, A., Lafontaine, M., et al. (2020) · JAMA Oncology · doi:10.1001/jamaoncol.2019.6143 · Cited by 631
Metadata
- Authors
- Weller, M., Felsberg, J., Hartmann, C., Berger, H., Steinbach, J. P., Schramm, J., Westphal, M., Schackert, G., Simon, M., Tonn, J. C., Heese, O., Krex, D., Nikkhah, G., Pietsch, T., Wiestler, O., Reifenberger, G., von Deimling, A., & Loeffler, M.
- Venue
- Journal of Clinical Oncology
- Published
- 2009-12-01
- Volume
- 27
- Issue
- 34
- Pages
- 5743-5750
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2127901599
- Cited by
- 614
- References
- 32
- FWCI
- 25.17
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.